



June 28, 2009

Dear Valued Customer,

On Friday Immucor publicly announced an FDA administrative action taken under a letter we received June 25, 2009. A copy of our press release has been posted on our website, www.immucor.com. We take our regulatory responsibilities very seriously and have been working diligently to improve our internal Quality System. As a valued business partner, we want you to know that this administrative action in no way impacts our ability to supply product to you and that the FDA did not order a recall of any of our products.

As you may recall, we received a warning letter from the FDA in May 2008 regarding concerns about our internal Quality System. Prior to receiving the warning letter, we had contracted with a third party consulting firm who is considered a global leader in quality systems improvement. In early 2009, we greatly expanded our efforts to improve our quality systems and processes through our Quality Process Improvement Project, which included a much larger role for our consultants. We expect to spend \$6 million to \$7 million on the Project. Upon its completion, we believe we will not only have addressed the FDA's concerns but we will have developed a world-class quality system that will enhance our abilities to service you, our Customer, in the future. We expect the Project to be completed no later than February 2010.

In January 2009, the FDA performed a follow-up inspection. Since the FDA's inspection in January 2009 we have kept them regularly informed of the Project's objectives and progress and have provided written updates to them on a monthly basis. The FDA's letter said the administrative action is based on their January 2009 inspection without mentioning the progress we have made in the last 6 months. The FDA has not performed an inspection since January 2009.

We remain in close contact with the FDA. We believe that we are doing everything necessary to address the FDA's concerns regarding our internal Quality System. Our Quality Process Improvement Project is a comprehensive, system-based approach to improving our Quality System and we are already well-along in the implementation process.

We would like to assure you that that the administrative action taken by the FDA on June 25, 2009 does not impact our ability to manufacture and distribute reagents that you require to operate your laboratory. We believe that our Quality Process Improvement Project will result in Immucor achieving a world-class quality system and we are committed to achieving this end as quickly as possible. We appreciate your partnership and continued support during this process.

Sincerely,

A handwritten signature in black ink, appearing to read "Nino De Chirico". The signature is written in a cursive style with a long, sweeping vertical line on the left side.

Dr. Nino De Chirico
President and CEO
Immucor, Inc.



HOW DOES THIS IMPACT THE PRODUCTS CURRENTLY IN MY LABORATORY:

- **Q: Are there recalls of any Immucor products?**
A: No, per the Immucor press release dated June 26, 2009, no products have been recalled by the FDA.
- **Q: Can I continue to use the products I currently have?**
A: Yes. The FDA letter does not impose any restrictions on the use of any Immucor reagents or instrumentation.
- **Q: Are my test results still considered tests of record?**
A: Yes. There is no impact to any Immucor reagents or instrumentation under the current administrative action.
- **Q: Does this require me to perform additional QC on Immucor reagents?**
A: No. You should continue to follow current procedures as outlined in product direction inserts. No additional test steps are required.

HOW DOES THIS IMPACT OUR BUSINESS RELATIONSHIP:

- **Q: Should I consider a new supplier to cover my needs?**
A: No. Immucor will continue to meet the needs of our business partners. The recent FDA letter does not interrupt our ability to manufacture and distribute product.
- **Q: Will this impact my ability to get my next standing order shipment?**
A: No interruptions to manufacturing and distribution are expected. Your next standing order will arrive as scheduled.
- **Q: Will this impact my ability to place orders with Immucor?**
A: No interruptions to manufacturing and distribution are expected. We will continue to accept and ship orders as usual.
- **Q: Will there be backorders on Anti-E or reagent red blood cells since these products were specifically mentioned in the FDA letter?**
A: No backorders are expected at this time. No interruptions to manufacturing and distribution are expected.
- **Q: How does this impact my instrument operations?**
A: The FDA letter has no impact on the distribution or servicing of our instruments. Also, because the FDA letter does not impact our ability to manufacture and distribute products, we do not anticipate any interruption to either your instrument or manual reagent supply.